中国实用妇科与产科杂志 ›› 2022, Vol. 38 ›› Issue (7): 687-691.DOI: 10.19538/j.fk2022070105

• 专题笔谈 • 上一篇    下一篇

低危妊娠滋养细胞肿瘤的治疗

  

  1. 中国医科大学附属盛京医院妇产科, 辽宁 沈阳 110004
  • 出版日期:2022-07-02 发布日期:2022-07-02
  • 通讯作者: 李秀琴

Treatment for low-risk gestational trophoblastic neoplasia. 

  1. Department of Obstetrics and Gynecology,Shengjing Hospital of China Medical University,Shenyang 110004,China 
  • Online:2022-07-02 Published:2022-07-02

摘要: 针对低危妊娠滋养细胞肿瘤(gestational trophoblastic neoplasia,GTN)的治疗,在国际妇产科联盟(FIGO)指南推荐的化疗基础上,应该再次分层,0~4分选择放线菌素-D(Act-D)或甲氨蝶呤(MTX)单药化疗,根据一些研究报道,Act-D的疗效优于MTX,而且副反应发生率更低;5~6分者目前建议单药化疗,但可放宽联合化疗方案的适应证。化疗期间密切监测疗效,如果单药化疗耐药,可以个体化的更换另一种单药或联合方案。

关键词: 妊娠滋养细胞肿瘤, 低危, 分层治疗

Abstract: The treatment of low-risk gestational trophoblastic neoplasia,based on the chemotherapy recommended by FIGO guidelines,should be stratified again,and actinomycin D(Act-D)or methotrexate(MTX) single-agent chemotherapy should be selected for those of 0-4 points. According to some research reports,the efficacy of Act-D is better than that of MTX,and the side effects are lower;single-agent chemotherapy is recommended for those with a score of 5-6,but the indications for combined chemotherapy can be broadened. The curative effect should be closely monitored during chemotherapy,and if the single-agent chemotherapy is resistant,another single-agent or combination regimen can be used individually.

Key words: gestational trophoblastic neoplasia, low-risk, stratified treatment

中图分类号: